Clinical value of peripheral blood circulating tumor cells in the diagnosis and treatment of prostate cancer
10.3760/cma.j.issn1008-6706.2022.05.010
- VernacularTitle:外周血循环肿瘤细胞在前列腺癌诊治中的临床应用价值
- Author:
Yawei ZHAO
1
;
Lei TANG
;
Qianyue LI
;
Wang MA
;
Zhikun LI
Author Information
1. 新疆生产建设兵团医院泌尿外科，乌鲁木齐 830002
- Keywords:
Prostatic neoplasms;
Carcinoma;
Neoplastic cells,circulating;
Prostate-specific antigen;
Neoplasm staging;
Early diagnosis;
Prognosis;
Tumor markers,biologic
- From:
Chinese Journal of Primary Medicine and Pharmacy
2022;29(5):683-687
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical value of peripheral blood circulating tumor cells (CTC) in the diagnosis and treatment of prostate cancer.Methods:Sixty-four patients with prostate cancer who received treatment in Xinjiang Production and Construction Corps Hospital, China between June 2018 and May 2020 were included in the cancer group. An additional 35 patients with benign prostatic lesions who concurrently received treatment in the same hospital were included in the benign disease group. Twenty male patients with non-prostate disease were included in the control group. Cell enrichment, separation, staining and identification together with Gleason score and pathological stage were subjected to one-way analysis of variance.Results:The percentage of patients with CTC count ≥ 3 in the cancer, benign disease and control groups was 73.43% (47/64), 17.14% (6/35) and 10.00% (2/20), respectively. The level of prostate-specific antigen in patients with CTC was significantly higher than that in patients without CTC ( t = 2.89, P < 0.05). There was significant difference in CTC count between different Gleason score groups ( F = 3.25, P < 0.05) and between different pathological stage groups ( F = 3.42, P < 0.05). Conclusion:Peripheral blood CTC measurement can be used as an auxiliary method for the differentiation of benign and malignant prostate diseases. CTC count in patients with prostate cancer is correlated with prostate-specific antigen level, Gleason score, and pathological stage. Therefore, peripheral blood CTC measurement plays an auxiliary role in predicting prognosis in patients with CTC. This study is innovative and scientific.
